FOMC adopts new policy strategy
- August 31, 2020
Balance Sheet Risk Management
Financial Institutions | Kennett Square, PA
The major U.S. equity indices moved higher on the week with the S&P 500 notching its fifth consecutive weekly gain amid positive COVID-19 vaccine developments and a host of encouraging economic data releases.
Prior week summary
The major U.S. equity indices moved higher on the week with the S&P 500 notching its fifth consecutive weekly gain amid positive COVID-19 vaccine developments and a host of encouraging economic data releases. In a highly anticipated announcement, the FOMC announced a change to its policy strategy on Thursday, opting to ditch its 2% inflation objective in favor of an average inflation target of 2%. The policy change was unanimously approved by all 17 top Fed officials and signals a more accommodative stance from the Federal Reserve as they add flexibility to the timing of future rate moves. In a statement released with the decision, the FOMC said, “The Committee seeks to achieve inflation that averages 2% over time and therefore judges that, following periods when inflation has been running persistently below 2%, appropriate monetary policy will likely aim to achieve inflation moderately above 2% for some time.” The change comes after years of falling short of its 2% inflation objective. While a mathematical calculation to determine this new 2% average goal was not released, St. Louis Fed President James Bullard suggested that such a calculation was not needed saying, “This is a very large committee as you know, with many opinions. So I don’t think you want to get into precise mathematical formulas here. But the spirit of this is that, in the committee’s judgment, it would be wise to allow inflation to be above targets for some time to make up for past misses.” On the economic data front, market participants received a deluge of economic data updates that largely pointed to a recovering U.S. economy. The housing market continued to see encouraging trends with new home sales at 901,000 in July, far above both consensus expectations and last month’s 791,000 figure. Durable goods orders smashed expectations after seeing an 11.2% increase in July, above the 7.7% pace seen in June. According to the second estimate of second-quarter GDP released by the Commerce Department, the U.S. economy shrank at an annualized 31.7% pace in the second quarter. Jobless claims continue to remain historically elevated with 1.01 million individuals filing for unemployment in the last week. Continuing jobless claims declined week over week to 14.54 million claims.
As of Sunday evening, the U.S. infection tally stands at 6.18 million cases, nearly a quarter of the global tally and a 5.1% increase week over week, with just over 187,000 individuals succumbing to the virus. After experiencing a surge in cases across the southern U.S. and California, cases have continued to decline in recent weeks with Florida seeing a 26% week over week decline and California and Texas seeing a 29% decrease in new cases over the same period. While the U.S. remains the most afflicted nation by confirmed case count, the 49,000 new cases reported on Friday is far below levels seen at the end of July amid the southern outbreak. After experiencing a modest rate of COVID-19 infections over the summer, many European countries, including France, Germany, and Italy, are now beginning to see an increase in infections and hospitalizations. On Thursday, France reported approximately 7,300 new cases, a figure not seen since the early days of the pandemic. While President Emmanuel Macron emphasized the need for social distancing and precautionary measures when speaking with reporters on Friday, he indicated that his government will do “everything to avoid a new lockdown.” FDA Commissioner Stephen Hahn turned heads last week after indicating that the FDA could fast track approval for a COVID-19 vaccine prior to the conclusion of Phase III trials in order to get the vaccine to the public as fast as possible. Speaking of a possible emergency authorization, Hahn said, “It is up to them to apply for authorization or approval, and we make an adjudication of their application. If they do that before the end of phase three, we may find that appropriate. We may find that inappropriate, we will make a determination.”
The look forward
Market participants are gearing up for a busy week of economic data releases with updated figures on the ISM Manufacturing Index, ISM Non-Manufacturing Index, ADP employment report, factory orders, jobless claims, and the August non-farm payroll report dotting the economic calendar.
Market implied policy path (Overnight indexed swap rates)
Chatham Hedging Advisors, LLC (CHA) is a subsidiary of Chatham Financial Corp. and provides hedge advisory, accounting and execution services related to swap transactions in the United States. CHA is registered with the Commodity Futures Trading Commission (CFTC) as a commodity trading advisor and is a member of the National Futures Association (NFA); however, neither the CFTC nor the NFA have passed upon the merits of participating in any advisory services offered by CHA. For further information, please visit chathamfinancial.com/legal-notices.
Transactions in over-the-counter derivatives (or “swaps”) have significant risks, including, but not limited to, substantial risk of loss. You should consult your own business, legal, tax and accounting advisers with respect to proposed swap transaction and you should refrain from entering into any swap transaction unless you have fully understood the terms and risks of the transaction, including the extent of your potential risk of loss. This material has been prepared by a sales or trading employee or agent of Chatham Hedging Advisors and could be deemed a solicitation for entering into a derivatives transaction. This material is not a research report prepared by Chatham Hedging Advisors. If you are not an experienced user of the derivatives markets, capable of making independent trading decisions, then you should not rely solely on this communication in making trading decisions. All rights reserved.20-0337
Our featured insights
The major U.S. equity indices ended the week mixed with the Dow Jones Industrial Average and the S&P 500 drifting lower and the Nasdaq inching higher amid mixed economic data, surging COVID-19 cases in the U.S., and encouraging vaccine developments from Pfizer and Moderna.
The major U.S. equity indices ended the week mixed with the Dow Jones Industrial Average and the S&P 500 moving higher and the Nasdaq heading lower amid rapidly rising COVID-19 cases in the U.S., mixed economic data updates, and encouraging COVID-19 vaccine developments.
The world is full of market and political shocks. Their timing/impact on markets are difficult to predict. Implementing a risk management policy and reviewing it regularly allows you to understand your material risk exposures, and how to control those risks based on predefined policy parameters.
The major U.S. equity indices marched higher last week, snapping a two-week stretch of declines and marking the best weekly performance since April, as investors digested a deluge of economic data releases, the U.S. presidential election, third-quarter corporate earnings, and rising COVID-19 cases.
The major U.S. equity indices moved lower last week, notching a second consecutive week of declines and marking the worst weekly performance since March, as rising COVID-19 cases in the U.S. and Europe coupled with news of renewed lockdowns in France, Germany, and the UK soured investor sentiment.
The major U.S. equity indices snapped a three-week stretch of gains, moving lower for the week, as investor sentiment soured amid stalling stimulus package negotiations on Capitol Hill and surging COVID-19 cases in the U.S. and Europe.
On Friday, October 23, the International Swaps and Derivatives Association (ISDA) launched the IBOR Fallbacks Supplement and Protocol, which provides a framework for transitioning interest rate derivatives from USD LIBOR to SOFR.
Despite faltering stimulus bill negotiations, rising COVID-19 cases in the U.S. and Europe, and troubling COVID-19 vaccine developments, the major U.S. equity indices marched higher for the third consecutive week.